

8th International Conference on REPRODUCTIVE HEALTH, EMBRYOLOGY AND FERTILITY

July 11, 2023 | Webinar

PsycheTox: Women and alcohol dependency: Hope from new therapeutics possibilities from psychedelic or not?

Raphael Serreau

Paris-Saclay University, France

Introduction: Synthesis of psychedelics for a new addictolytic treatment in alcoholism: Is this treatment compatible with pregnancy or breastfeeding period? Psychedelics are of increasing interest in the management of patients suffering from alcohol addiction. Several addictolytic treatments exist but the effectiveness remains modest in maintaining abstinence in alcoholic patients. Women are increasingly affected by alcohol addiction, especially during the reproductive period. The question arises of the teratogenic and fetotoxic risk of exposure to alcohol and taking medication to avoid alcohol dependence. Obtain the synthesis of a new drug in the management of patients suffering from severe alcohol use disorders.

It seems important to verify the reproductive risk of these new molecules in order to consider whether their future use in pregnant or breastfeeding women or not.

Materials and methods:

- Development of a pharmaceutical circuit of psychedelics.
- Composition of the capsules according to good pharmaceutical practices.
- Access to a CNRS technical platform in Orleans with a chemist for clinical trials following ANSM recommendations.
- Work on Reprotox and Lactmed databases to assess teratogenicity potential of psychedelic drugs.

Results and conclusions: As of November 25, 2022, successful synthesis of psychedelics for future clinical trials, Study of the teratogenicity of molecules during pregnancy and breastfeeding. We need now evaluate potential teratogenicity of psychedelic drugs. We are working with a new biomolecular platform for fundamental research.

Biography

Raphael Serreau is a French medical doctor and a scientist for 20 years. He has done his medical study in Tours and Paris in France. He is a Pharmacology teacher for the midwives since 1997. Upon completion of his doctorate in Pharmacology at the University of Paris V René Descartes in 2007 about Risk Management Plan during pregnancy and breastfeeding, He was the responsible of the Medic-Al network in Necker Hospital in Paris to January 2017. Since 2013 and 15th March 2019, He received a habilitation to manage clinical study (HDR) in Burgundy University in Dijon (CNU 48-03). He joined the Research Team of Prof. Amine Benyamina in AP-HP University Paris Saclay Hospitals: UR Psycomadd. Since the 11th of March 2020, he creates the Clinical Research Unit "PARADICT-O" in Orléans Métropole. He joined the EPSM Georges DAUMEZON Hospital as a Public Health Specialist in Addictions in September 2021.

raphael.serreauurc@gmail.com